Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Opthea Ltd Capital/Financing Update 2017

Apr 2, 2017

32698_rns_2017-04-02_96d20425-4bf8-4866-a66e-fd02e22c7bee.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Opthea Limited ( Opthea )

ABN

32 006 340 567

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1
+Class of+securities issued or to
be issued
2
Number of+securities issued or
to be issued (if known) or
maximum number which may
be issued
Fully paid ordinary shares (Shares)
Approximately 37,554,377 Shares under the
institutional
placement
announced
by
Opthea on 3 April 2017 (Placement).
Approximately 10,832,720 Shares under the
pro-rata
accelerated
non-renounceable
entitlement offer announced by Opthea on
3 April 2017 (Entitlement Offer).
The exact number of Shares to be issued
under the Placement and the Entitlement
Offer, and the split of Shares between the
institutional component of the Entitlement
Offer (Institutional Entitlement Offer)
and the retail component of the Entitlement
Offer (Retail Entitlement Offer), is not
known at the date of this Appendix 3B as it
remains subject to (among other things) the
determination
of
the
Company,
the
3
Principal terms of the+securities
(e.g. if options, exercise price
and expiry date; if partly paid
+securities,
the
amount
outstanding and due dates for
payment;
if
+convertible
securities, the conversion price
and dates for conversion)
4
Do the+securities rank equally
in all respects from the+issue
date with an existing+class of
quoted+securities?
If the additional+securities do
not rank equally, please state:
• the date from which they do
• the extent to which they
participate
for
the
next
dividend, (in the case of a
trust,
distribution)
or
interest payment
• the extent to which they do
not rank equally, other than
in
relation
to
the
next
dividend,
distribution
or
interest payment
5
Issue price or consideration
reconciliation
of
security
holder
entitlements and the effects of rounding.
21,000 Shares were also issued pursuant to
the exercise of options.
Same as existing quoted Shares.
Yes.
Shares issued under the Placement will not
be entitled to participate in the Entitlement
Offer.
In respect of the Placement and Entitlement
Offer, $0.93 per Share.
In respect of the issue of options, $0.27 per
share.
  • See chapter 19 for defined terms.

Appendix 3B Page 2

04/03/2013

6
Purpose of the issue
(If issued as consideration for
the acquisition of assets, clearly
identify those assets)
6a
Is the entity an+eligible entity
that
has
obtained
security
holder approval under rule 7.1A?
If Yes, complete sections 6b – 6h
in relation to the+securities the
subject of this Appendix 3B, and
comply with section 6i
6b
The date the security holder
resolution under rule 7.1A was
passed
6c
Number of+securities issued
without security holder approval
under rule 7.1
6d
Number of+securities issued
with security holder approval
under rule 7.1A
6e
Number of+securities issued
with security holder approval
under rule 7.3, or another
specific security holder approval
(specify date of meeting)
6f
Number of+securities issued
under an exception in rule 7.2
As described in the ASX announcement and
investor presentation lodged with ASX on 3
April 2017 – namely, to raise capital to,
amongst other things, fund clinical trials of
Opthea’s drug compound, OPT-302, in a
phase 2B clinical trial for wet age related
macular degeneration and a phase 2A
clinical trial for treating diabetic macular
edema patients.
21,000 Shares have been issued pursuant to
the exercise ofquoted options
Yes
28 November 2016
The exact number of shares to be issued is
not known at the date of this Appendix 3B
as it remains subject to (among other
things) the determination of the Company,
the
reconciliation
of
security
holder
entitlements and the effects of rounding.
Refer to item 2.
Refer to item 6c.
N/A.
Refer to item 6c.

6g If[+] securities issued under rule To be confirmed on the date of issue of 7.1A, was issue price at least 75% Placement shares under Listing Rule 7.1A of 15 day VWAP as calculated (scheduled for Wednesday, 12 April 2017) under rule 7.1A.3? Include the +issue date and both values. and calculated in accordance with Listing Include the source of the VWAP Rule 7.1A.3(b). calculation. 6h If[+] securities were issued under N/A rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining See Annexure 1. issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 +Issue dates 29 March 2017 in respect of the exercise of Note: The issue date may be prescribed by ASX (refer to the definition of issue date in quoted options. rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A. 12 April 2017 for Shares issued under the Cross reference: item 33 of Appendix 3B. Placement and the Institutional Entitlement Offer. 3 May 2017 for Shares issued under the Retail Entitlement Offer.

8
Number
and
+class
of
all
+securities
quoted
on
ASX
(_including_the
+securities in
section 2 if applicable)
Number +Class
After completion of
the Placement and
Entitlement
Offer,
there
will
be
approximately
200,045,175
Shares
on issue (based on
151,658,078
Shares
on issue as at the
date
of
this
Appendix 3B and the
aggregate
approximate number
of
Shares
to
be
issued
under
the
Placement and the
Entitlement Offer as
specified in item 2 of
this Appendix 3B).
Fully paid ordinary
shares
  • See chapter 19 for defined terms.

Appendix 3B Page 4

04/03/2013

Quoted options 48,254,922

  • 9 Number and +class of all +securities not quoted on ASX ( including the +securities in section 2 if applicable)
Number +Class
1,000,000
7,000,000
2,625,000
Unquoted
options
issued to Bell Potter
Securities
Limited
pursuant
to
a
Corporate Advisory
Agreement.
Unquoted
options
issued to directors of
Opthea.
Unquoted
options
issued to employees
of Opthea.

10 Dividend policy (in the case of a Same as existing Shares, from the date of trust, distribution policy) on the issue. increased capital (interests) The ability of the Company to offer dividends (if any) is contingent on it making taxable profits. The determination of any dividend is at the absolute discretion of the directors.

Part 2 - Pro rata issue

Part 2 - Pro rata issue
11
Is
security
holder
approval
required?
12
Is the issue renounceable or non-
renounceable?
13
Ratio in which the+securities
will be offered
14
+Class of+securities to which the
offer relates
15
+Record
date
to
determine
entitlements
No
Non-renounceable
1 Share for every 14 Shares held as at the
record date for the Entitlement Offer.
Fully paid ordinary shares.
7.00pm (AEST) on 5 April 2017.
16
Will
holdings
on
different
registers (or subregisters) be
aggregated
for
calculating
entitlements?
17
Policy for deciding entitlements
in relation to fractions
18
Names of countries in which the
entity has security holders who
will not be sent new offer
documents
Note: Security holders must be told how their
entitlements are to be dealt with.
Cross reference: rule 7.7.
19
Closing
date
for
receipt
of
acceptances or renunciations
20
Names of any underwriters
21
Amount of any underwriting fee
or commission
22
Names of any brokers to the
issue
23
Fee or commission payable to the
broker to the issue
24
Amount of any handling fee
payable to brokers who lodge
acceptances or renunciations on
behalf of security holders
25
If the issue is contingent on
security holders’ approval, the
date of the meeting
No.
Where fractions arise in the calculation of
the shareholders’ entitlements under the
Entitlement Offer they will be rounded up
to the next whole number of Shares.
Under the Retail Entitlement Offer, all
countries other than Australia and New
Zealand.
Under the Institutional Entitlement Offer,
all countries other than Australia, New
Zealand, the United States, Hong Kong,
Singapore, Finland, Germany, Switzerland,
Israel and the United Kingdom.
Institutional
Entitlement
Offer
closes
Tuesday 4 April 2017.
Retail Entitlement Offer closes 24 April
2017.
The Institutional Entitlement Offer and
Retail Entitlement Offer
N/A
N/A
N/A
N/A
N/A
  • See chapter 19 for defined terms.

Appendix 3B Page 6

04/03/2013

26 Date entitlement and acceptance No prospectus is being prepared. form and offer documents will be sent to persons entitled A retail offer booklet and entitlement and acceptance form in respect of the Retail Entitlement Offer will be sent to eligible retail security holders on or around 10 April 2017. 27 If the entity has issued options, N/A and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if N/A applicable) 29 Date rights trading will end (if N/A applicable) 30 How do security holders sell N/A their entitlements in full through a broker? 31 How do security holders sell part N/A of their entitlements through a broker and accept for the balance? 32 How do security holders dispose N/A of their entitlements (except by sale through a broker)? 33 +Issue date Refer to item 7 of this Appendix 3B.

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

  • 34 Type of[+] securities ( tick one )

  • (a) +Securities described in Part 1

  • (b)[All other ][+][securities ]

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid,

employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

  • 35 If the[+] securities are[+] equity securities, the names of the 20 largest holders of the additional[+] securities, and the number and percentage of additional[+] securities held by those holders

  • 36 If the[+] securities are[+] equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

  • 1 - 1,000

  • 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over

  • 37 A copy of any trust deed for the additional[+] securities

  • See chapter 19 for defined terms.

Appendix 3B Page 8

04/03/2013

Entities that have ticked box 34(b)

38 Number of[+] securities for which N/A +quotation is sought 39 +Class of +securities for which N/A quotation is sought 40 Do the[+] securities rank equally in N/A all respects from the[+] issue date with an existing[+] class of quoted +securities? If the additional[+] securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation N/A now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another[+] security, clearly identify that other[+] security) Number +Class 42 Number and +class of all N/A N/A +securities quoted on ASX ( including the[+] securities in clause 38)

Quotation agreement

  • 1 +Quotation of our additional +securities is in ASX’s absolute discretion. ASX may quote the[+] securities on any conditions it decides.

  • 2 We warrant the following to ASX.

  • The issue of the[+] securities to be quoted complies with the law and is not for an illegal purpose.

  • There is no reason why those[+] securities should not be granted +quotation.

  • An offer of the[+] securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

  • Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any[+] securities to be quoted and that no-one has any right to return any[+] securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the[+] securities be quoted.

  • If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the[+] securities be quoted.

  • 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

  • 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

3 April 2017 Sign here: ............................................................ Date: .........................

Company secretary

Mike Tonroe

Print name: .........................................................

== == == == ==

  • See chapter 19 for defined terms.

Appendix 3B Page 10

04/03/2013

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

==> picture [414 x 403] intentionally omitted <==

----- Start of picture text -----

Insert number of fully paid [+] ordinary 150,190,303 shares
securities on issue 12 months before the
+ issue date or date of agreement to issue
Add the following: 15,500 shares (issued 18 May 2016)
30,900 shares (issued 7 October 2016)
• Number of fully paid [+] ordinary securities
issued in that 12 month period under an 1,400,375 shares (issued 3 February 2017)
exception in rule 7.2
21,000 shares (issued 29 March 2017)
• Number of fully paid [+] ordinary securities
issued in that 12 month period with
shareholder approval
• Number of partly paid [+] ordinary
securities that became fully paid in that
12 month period
Note:
• Include only ordinary securities here –
other classes of equity securities cannot
be added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Subtract the number of fully paid [+] ordinary None
securities cancelled during that 12 month
period
“A” 151,658,078 shares
----- End of picture text -----

  • See chapter 19 for defined terms.

Appendix 3B Page 11

04/03/2013

Step 2: Calculate 15% of “A”

Step 2: Calculate 15% of “A” Step 2: Calculate 15% of “A”
“B” 0.15
[Note: this value cannot be changed]
Multiply“A” by 0.15 22,748,711 shares
Step 3: Calculate “C”, the amount of placement capacity under rule
7.1 that has already been used
Insertnumber of+equity securities issued
or agreed to be issued in that 12 month
period_not counting_those issued:
• Under an exception in rule 7.2
• Under rule 7.1A
• With security holder approval under rule
7.1 or rule 7.4
Note:
• This applies to equity securities, unless
specifically excluded – not just ordinary
securities
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
None.
“C” None.
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining
placement capacity under rule 7.1
“A” x 0.15
Note: number must be same as shown in
Step 2
22,748,711 shares
Subtract“C”
Note: number must be same as shown in
Step 3
None
Total[“A” x 0.15] – “C” Up to 22,748,711 shares
[Note: this is the remaining placement
capacity under rule 7.1]

placement capacity under rule 7.1
“A” x 0.15 22,748,711 shares
Note: number must be same as shown in
Step 2
Subtract“C” None
Note: number must be same as shown in
Step 3
Total[“A” x 0.15] – “C” Up to 22,748,711 shares
[Note: this is the remaining placement
capacity under rule 7.1]
  • See chapter 19 for defined terms.

Appendix 3B Page 12

04/03/2013

Part 2

Part 2 Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement
capacity is calculated
“A”
Note: number must be same as shown in
Step 1 of Part 1
151,658,078 shares
Step 2: Calculate 10% of “A”
“D” 0.10
Note: this value cannot be changed
Multiply“A” by 0.10 15,165,807
Step 3: Calculate “E”, the amount of placement capacity under rule
7.1A that has already been used
Insertnumber of+equity securities issued
or agreed to be issued in that 12 month
period under rule 7.1A
Notes:
• This applies to equity securities – not
just ordinary securities
• Include here – if applicable – the
securities the subject of the Appendix
3B to which this form is annexed
• Do not include equity securities issued
under rule 7.1 (they must be dealt with
in Part 1), or for which specific security
holder approval has been obtained
• It may be useful to set out issues of
securities on different dates as separate
line items
None.
“E” None.
  • See chapter 19 for defined terms.

Appendix 3B Page 13

04/03/2013

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
Step 4: Subtract “E” from [“A” x “D”] to calculate remaining
placement capacity under rule 7.1A
“A” x 0.10
Note: number must be same as shown in
Step 2
15,165,807
Subtract“E”
Note: number must be same as shown in
Step 3
None.
Total[“A” x 0.10] – “E” Up to 15,165,807
Note: this is the remaining placement
capacity under rule 7.1A
  • See chapter 19 for defined terms.

Appendix 3B Page 14

04/03/2013